Search Results

Business

Photocure ASA: Results for the first quarter of 2024

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024, and EBITDA of NOK 7.9 million following positive operational developments and cost control.

May 15, 2024

·

5 min read

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure ASA, the Bladder Cancer Company, announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy using a mobile capital equipment model.

June 4, 2024

·

8 min read

Photocure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Photocure ASA, The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024.

April 5, 2024

·

1 min read

Business

Photocure ASA: Results for the fourth quarter of 2023

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period, and EBITDA of NOK 29.9 million following solid business development for the Company.

February 21, 2024

·

5 min read

Business

Photocure ASA: Change of Board Composition

Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.

September 27, 2023

·

1 min read

Business

Photocure ASA: Results for the third quarter of 2023

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023, and an EBITDA of NOK 3.3 million for the company.

November 8, 2023

·

5 min read

Photocure to present at four investor conferences in November/December 2023

Photocure ASA, The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

November 20, 2023

·

1 min read

Drug Development

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.

March 18, 2024

·

5 min read

Policy

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration accepted the new drug application for Hexvix® in China.

November 29, 2023

·

5 min read

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

CollPlant Biotechnologies announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant’s photocurable dermal filler product candidate, being developed for the aesthetics market.

November 1, 2023

·

5 min read